DENVER, Colo.--(BUSINESS WIRE)--The Sorin Group (MIL:SRN), the largest European cardiovascular company and world leader in medical technologies for cardiac surgery, announced today that it has received the U.S. Food and Drug Administration’s authorization for marketing its MEMO 3D Semirigid Annuloplasty Ring in the USA.
Annuloplasty rings are indicated for repair of the mitral valve and are designed to remodel the anatomical shape of the mitral annulus, preventing further dilatation and minimizing the risk of late repair failures.
